Abstract
Concomitant radiotherapy and cetuximab association has shown superiority to exclusive radiotherapy for head and neck cancers. Data on this association are scarce for the elderly population despite its rising incidence. A retrospective monocentric data collection was performed in the Antoine Lacassagne Cancer Center in France. Inclusion criteria were: age >70 years at time of diagnosis, histologically proven head and neck epidermoid carcinoma, treated with radiotherapy combined with cetuximab. Thirty-five patients were included between 2008 and 2012. Median follow-up was 22 months. Median age was 74 years (70–86). Median performance status was 1 (0–2). Female/male sex ratio was 0.34. Tumor sites were: oropharynx (57.1 %), larynx (20 %), hypopharynx (14.3 %), oral cavity (2.9 %), nasopharynx (2.9 %), and lymph node with unknown primary (2.9 %). Using TNM classification, tumors were: T1 (5.9 %), T2 (35.3 %), T3 (35.3 %), T4 (22.9 %), N0 (28.6 %), N1 (8.6 %), N2 (48.6 %), and N3 (14.3 %). Median radiotherapy dose was 70 (60–70). RT was interrupted in 94 % of patients and the dose of cetuximab was reduced in 29 %. Median survivals were, respectively: 49 months for overall survival (standard error (SE) = 8) and 32 months for relapse-free survival (SE = 10). Two-year local–regional relapse and metastatic relapse-free survivals were, respectively, 59 % (SE = 10) and 74 % (SE = 10). Concomitant radiotherapy and cetuximab seem to be an effective therapy in the elderly population with encouraging results similar to the literature concerning its efficacy and toxicity. This treatment should be considered for patients >70 years.
Similar content being viewed by others
References
United Nation—Population Division—Departments of Economic and Social Affairs—Population AGEING 2002 (Internet) (cité 17 Déc 2015). Disponible sur: http://www.un.org/esa/population/publications/ageing/Graph.pdf
Balducci L, Beghe’ C (2001) Cancer and age in the USA. Crit Rev Oncol Hematol 37(2):137–145
Bernardi D, Barzan L, Franchin G, Cinelli R, Balestreri L, Tirelli U et al (2005) Treatment of head and neck cancer in elderly patients: state of the art and guidelines. Crit Rev Oncol Hematol 53(1):71–80
Pignon J-P, Le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol J Eur Soc Ther Radiol Oncol 92(1):4–14
Lionello M, Blandamura S, Lovato A, Franchella S, Giacomelli L, Ottaviano G et al (2013) A high nuclear nm23-H1 expression is associated with a better prognosis in elderly patients with laryngeal carcinoma. Acta Otolaryngol (Stockh) 133(8):874–880
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578
Lovato A, Marioni G, Manzato E, Staffieri C, Giacomelli L, Ralli G et al (2014) Elderly patients at higher risk of laryngeal carcinoma recurrence could be identified by a panel of two biomarkers (nm23-H1 and CD105) and pN+ status. Eur Arch Otorhinolaryngol 272(11):3417–3424
Sobin LH, Gospodarowicz MK, Wittekind C (2014) TNM classification of malignant tumours, 7th edn (Internet) (cité 31 Juill 2014). Disponible sur: http://eu.wiley.com/WileyCDA/WileyTitle/productCd-1444332414.html
Protocol Development, CTEP (Internet) (cité 4 Juill 2016). Disponible sur: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
Sarris EG, Harrington KJ, Saif MW, Syrigos KN (2014) Multimodal treatment strategies for elderly patients with head and neck cancer. Cancer Treat Rev 40(3):465–475
Magrini SM, Buglione M, Corvò R, Pirtoli L, Paiar F, Ponticelli P et al (2015) Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol
Russi EG, Moretto F, Rampino M, Benasso M, Bacigalupo A, De Sanctis V et al (2015) Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: literature review and consensus. Crit Rev Oncol Hematol 96(1):167–182
Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079–1095
Ortholan C, Benezery K, Dassonville O, Poissonnet G, Bozec A, Guiochet N et al (2011) A specific approach for elderly patients with head and neck cancer. Anticancer Drugs 22(7):647–655
Ghadjar P, Hayoz S, Zimmermann F, Bodis S, Kaul D, Badakhshi H et al (2015) Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94). Radiat Oncol Lond Engl 10:21
Shaw SM, Flowers H, O’Sullivan B, Hope A, Liu LWC, Martino R (2015) The effect of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement on swallowing and swallow-related outcomes in patients undergoing radiotherapy for head and neck cancer: a systematic review. Dysphagia 30(2):152–175
Montero PH, Patel SG (2015) Cancer of the oral cavity. Surg Oncol Clin N Am 24(3):491–508
González Ferreira JA, Jaén Olasolo J, Azinovic I, Jeremic B (2015) Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature. Rep Pract Oncol Radiother J Gt Cancer Cent Pozn Pol Soc Radiat Oncol 20(5):328–339
Fowler JF, Lindstrom MJ (1992) Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23(2):457–467
Ho C (2010) Cetuximab in locally advanced head-and-neck cancer: defining the population. Curr Oncol 17(4):48–51
Kataria T, Gupta D, Bisht SS, Goyal S, Basu T, Srivastava A et al (2015) Chemoradiation in elderly patients with head and neck cancers: a single institution experience. Am J Otolaryngol 36(2):117–121
Jensen AD, Bergmann ZP, Garcia-Huttenlocher H, Freier K, Debus J, Münter MW (2010) Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck(SCCHN) in the elderly and multi-morbid patient: a single-centre experience. Head Neck Oncol 2:34
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they do not have conflict of interests.
Research involving humans
This retrospective study received approval by the local ethics committee.
Rights and permissions
About this article
Cite this article
Falk, A.T., Hébert, C., Tran, A. et al. Radiotherapy for elderly patients and cetuximab, a monocentric study. Eur Arch Otorhinolaryngol 274, 1061–1065 (2017). https://doi.org/10.1007/s00405-016-4336-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-016-4336-3